A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2030

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan

T-DXd: administered as an IV infusion

DRUG

Durvalumab

Durvalumab: administered as an IV infusion

DRUG

Paclitaxel

Paclitaxel: administered as an IV infusion

DRUG

Pertuzumab

Pertuzumab: administered as an IV infusion

DRUG

Tucatinib

Tucatinib administered orally (tablet) twice daily

Trial Locations (72)

114

Research Site, Taipei

168

Research Site, Rome

235

Research Site, Taipei

333

Research Site, Taoyuan

704

Research Site, Tainan City

970

Research Site, Hualien City

3000

Research Site, Melbourne

6100

Research Site, Ankara

10016

Research Site, New York

10048

Research Site, Taipei

10065

Research Site, New York

10449

Research Site, Taipei

10604

Research Site, Harrison

11217

Research Site, Taipei

11725

Research Site, Commack

20141

Research Site, Milan

22030

Research Site, Edirne

22031

Research Site, Fairfax

28007

Research Site, Madrid

28050

Research Site, Madrid

33705

Research Site, St. Petersburg

33901

Research Site, Fort Myers

34662

Research Site, Istanbul

34722

Research Site, Istanbul

35100

Research Site, Izmir

37203

Research Site, Nashville

40138

Research Site, Bologna

41013

Research Site, Seville

43219

Research Site, Columbus

76104

Research Site, Fort Worth

80131

Research Site, Napoli

81675

Research Site, München

94805

Research Site, Villejuif

97080

Research Site, Würzburg

105229

Research Site, Moscow

109240

Research Site, Moscow

110085

Research Site, Delhi

111123

Research Site, Moscow

115478

Research Site, Moscow

117997

Research Site, Moscow

121205

Research Site, Moscow

122001

Research Site, Gūrgaon

143423

Research Site, Moscow

195271

Research Site, Saint Petersburg

196603

Research Site, Saint Petersburg

197758

Research Site, Saint Petersburg

400012

Research Site, Mumbai

625107

Research Site, Madurai

14784-400

Research Site, Barretos

30150-274

Research Site, Belo Horizonte

59075-740

Research Site, Natal

90610-000

Research Site, Porto Alegre

91350-200

Research Site, Porto Alegre

20560-120

Research Site, Rio de Janeiro

01317-001

Research Site, São Paulo

04029-000

Research Site, São Paulo

18030-005

Research Site, Sorocaba

H2X 0A9

Research Site, Montreal

G1S 4L8

Research Site, Québec

M5G 2M9

Research Site, Toronto

85-796

Research Site, Bydgoszcz

75-581

Research Site, Koszalin

90-242

Research Site, Lodz

20-090

Research Site, Lublin

602-739

Research Site, Busan

02841

Research Site, Seoul

03080

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

08003

Research Site, Barcelona

08908

Research Site, L'Hospitalet de Llobregat

IG9 5HX

Research Site, Buckhurst Hill

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Daiichi Sankyo Company, Limited

UNKNOWN

lead

AstraZeneca

INDUSTRY

NCT04538742 - A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter